The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

It has been documented that statin reduce mortality and morbidity in patients with cardiovascular disease. This effect can partly be related to a reduction in cholesterol levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as nephropathy, diabetes and hypertension. The purpose of this study is to investigate the effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular variables in patients with type 2 diabetes with nephropathy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erling Bjerregaard Pedersen
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Men and women

• minimum 40 years

• Chronic Kidney disease

• Estimated GFR (eGFR) between 30 and 90 ml/min

• Diabetes Mellitus type II

Exclusion Criteria:

• Nephrotic Syndrome

• Anamnestic or clinical signs of significant heart, lung, lever, kidney and brain disease

• Neoplastic disease

• Alcohol abuse,

• Drug abuse

• Pregnancy or nursing

• Blood donation within a month before examination

• Hgb < 6,0